USA Domestic Delivery,Canada Domestic Delivery,European Domestic Delivery

Hydroxyprogesterone caproate powder

Rating:
5.00 out of 5 based on 1 customer rating
SKU: 630-56-8. Category:

AASraw is with synthesis and production ability from gram to mass order of Hydroxyprogesterone caproate powder (630-56-8), under CGMP regulation and trackable quality control system.

Hydroxyprogesterone caproate powder is a synthetic steroid hormone that is similar to medroxyprogesterone acetate and megestrol acetate. It is an ester derivative of 17α-hydroxyprogesterone formed from caproic acid (hexanoic acid). Hydroxyprogesterone caproate was previously marketed under the brand name MAKENA.

Product Description

 

Hydroxyprogesterone caproate powder video

 

 


 

Hydroxyprogesterone caproate powder basic Characters

 

Name: Hydroxyprogesterone caproate powder
CAS: 630-56-8
Molecular Formula: C27H40O4
Molecular Weight: 428.6
Melt Point: 120°-124°C
Storage Temp: RT
Color: White powder

 


 

Hydroxyprogesterone caproate powder

 

Names

Chemical Names:Hydroxyprogesterone caproate powder
Brand Names: Hydroxyprogesterone caproate(OHPC) powder, Delalutin powder, Proluton powder, 630-56-8

 

Hydroxyprogesterone caproate powder Usage

THIS INFORMATION IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE USED AS A SOURCE FOR MAKING PRESCRIBING OR OTHER MEDICAL DETERMINATIONS.

1) For preterm delivery prophylaxis in females with a singleton pregnancy who have a history of singleton spontaneous preterm birth.

Intramuscular dosage (single and multi-dose vials Makena only)
Adult and Adolescent pregnant females 16 years and older
250 mg (1 mL) IM once weekly (every 7 days). Begin treatment anytime between 16 weeks and 0 days of pregnancy up to 20 weeks and 6 days of pregnancy. Continue once weekly until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first. The effectiveness of hydroxyprogesterone is based on improvement in the proportion of women who delivered at less than 37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. LIMITATION OF USE: Hydroxyprogesterone is not intended for use in women with multiple gestations or other risk factors for preterm birth.

Subcutaneous dosage (Makena auto-injector only)
Adult and Adolescent pregnant females 16 years and older
275 mg (1.1 mL) subcutaneously once weekly (every 7 days). Begin treatment anytime between 16 weeks and 0 days of pregnancy up to 20 weeks and 6 days of pregnancy. Continue once weekly until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first. The effectiveness of hydroxyprogesterone is based on improvement in the proportion of women who delivered at less than 37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. LIMITATION OF USE: Hydroxyprogesterone is not intended for use in women with multiple gestations or other risk factors for preterm birth.

2) For the treatment of inoperable, recurrent, and metastatic endometrial cancer.

Intramuscular dosage
Adult females
1,000 mg or more per week IM (range 1 gram IM once weekly to 1 gram IM once daily). Discontinue when relapse occurs, or after 12 weeks with no objective response. May be used in advanced stage concomitantly with other anticancer therapy (surgery, a radiation, or chemotherapy, or combination of these). Treatment results reported to date have been better in histologically well-differentiated forms of endometrial adenocarcinoma.

3) For the treatment of amenorrhea (primary or secondary) or for dysfunctional uterine bleeding due to hormonal imbalance in the absence of organic pathology.

Intramuscular dosage
Adult and Adolescent females
375 mg IM as a single dose, given at any time. Next dose may begin after 4 days of desquamation or, if there is no bleeding, 21 days after the initial single dose. If no response after 4 cycles, discontinue. The number of cycles used and when to use cyclic dosing is dependent on the indication for use and whether estrogen therapy is used concurrently. A suggested cyclic cycle with estrogen is as follows (28-day cycle; repeated every 4 weeks) Day 1 of each cycle: Estradiol Valerate Injection (20 mg IM); then, 2 weeks after Day 1: Hydroxyprogesterone caproate powder 250 mg IM; then Estradiol Valerate (5 mg IM) 4 weeks after Day 1: This is Day 1 of the next cycle. Repeat as indicated. If estrogen deficiency has been prolonged in patients with amenorrhea, menstruation may not occur until estrogen has been given for several months. Discontinue when cyclic therapy no longer required.
To test for endogenous estrogen production (“Medical D and C”).
Intramuscular dosage
Adult females
250 mg IM once; repeat for confirmation at 4 weeks after the first injection. Discontinue after the second dose. Bleeding should occur 7 to 14 days after the injection.

 

Warning on Hydroxyprogesterone caproate powder

Hydroxyprogesterone caproate powder injection, including compounded products, meet the definition of medical necessity when used to reduce the risk of preterm birth in a female member and ALL of the following criteria are met:

1. The member has a current singleton pregnancy.
2. The member has a documented previous singleton spontaneous preterm birth that occurred at less than 37 weeks gestation due to spontaneous preterm labor or premature rupture of membranes.
3. Member has not had any preterm labor or premature rupture of membranes during the current pregnancy.
4. Treatment is initiated between 16 weeks, 0 days and 20 weeks, 6 days of gestation.
5. Injections are not to be administered more often than weekly until 36 weeks of gestation or time of delivery (whichever occurs first) for a maximum total of no more than 21 injections.
6. Dose does not exceed 250 mg per injection.

 

Further instructions

The chemical name for Hydroxyprogesterone caproate powder is pregn-4-ene-3,20-dione, 17[(1oxohexyl)oxy]. It has an empirical formula of C27H40O4 and a molecular weight of 428.60. Hydroxyprogesterone caproate powder exists as white to practically white crystals or powder with a melting point of 120°-124°C.

Hydroxyprogesterone caproate powder mechanism of action: the mechanism by which progesterone prevents preterm birth is not well understood, but many pathways are likely involved.Progesterone plays a vital role in regulation of the female reproductive system and is important for successful implantation of the embryo and maintenance of pregnancy. It acts by binding to progesterone receptors in the uterus, ovaries, breasts and in the central nervous system. These receptors exist in 2 isoforms, PR-A and PR-B. Progesterone binding to these receptors ultimately leads to regulation of gene transcription.This results in an anti-inflammatory effect which blunts the proinflammatory state that occurs with initiation of labor, and maintains uterine queiscence by stabilizing progesterone acting on the myometrium.

Pharmacodynamics of Hydroxyprogesterone caproate powder: No specific pharmacodynamic studies have been performed to assess Hydroxyprogesterone caproate powder injections. However, the mechanism of action is likely related to increased interaction between progesterone and progesterone receptors.

Hydroxyprogesterone caproate powder half life is 16 days (±6 days).

 

Hydroxyprogesterone caproate powder Raw Powder

Min order 10grams.
The inquiry on normal quantity(Within 1kg) can be sent out in 12 hours after payment.
For larger order(Within 1kg)can be sent out in 3 workingdays after payment.

 

Hydroxyprogesterone caproate powder Marketing

To be provided in the coming future.

 


 

How to buy Hydroxyprogesterone caproate powder from AASraw

 

1.To contact us by our email inquiry system,or online skypecustomer service representative(CSR).
2.To provide us your inquired quantity and address.
3.Our CSR will provide you the quotation, payment term, tracking number, delivery ways and estimated arrival date(ETA).
4.Payment done and the goods will be sent out in 12 hours(For order within 10kg).
5.Goods received and give comments.

 

 


=

COA

COA 630-56-8 Hydroxyprogesterone caproate powder AASRAW

HNMR

630-56-8 Hydroxyprogesterone caproate AASRAW HMNR

Recipes

References & product citations